Navigation Links
Reportlinker Adds The Clinical Trials Business
Date:12/14/2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Clinical Trials Business

http://www.reportlinker.com/p0341185/The-Clinical-Trials-Business.html

New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.  Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014. 

In 2010, the number of clinical trials in the U.S. is 25,992. This number is expected to increase at a 5.7% compound annual growth rate (CAGR) to reach 32,318 in 2014.

Pharmaceutical and biotechnology companies devote a greater percentage of their budgets to R&D than does any other U.S. industry.  In 2009, the pharmaceutical industry invested 34.8% of sales in domestic R&D. In 2014, this percentage is projected to increase to 48.8, a 7% compound annual growth rate (CAGR).

STUDY GOALS AND OBJECTIVESThis report is designed to provide readers with a comprehensive understanding of the clinical trials process and its role in the research and development of new medicines in the U.S. It will provide an overview of clinical trials, including phases of clinical trials, U.S. government regulations, international regulations, costs of clinical trials, technologies, contract research organizations (CROs), and other factors. This report will forecast trends and clinical trial costs through 2014.

Generally, clinical trials are performed on drugs that have undergone a long test period. What are some of the factors that are and will bring drugs/devices as far as the clinical trial? What percentage of new chemical entities/proposals makes it to clinical trial? Who benefits from clinical trials, medically and financially? These areas will be reviewed and analyzed in this report.

REASONS FOR DOING THE STUDYThe mapping of the human genome has opened new possibilities for the development of new medications to treat disease. Genomics, the emerging field of study resulting from the Human Genome Project, is coupling with bioengineering technology and biotechnology, producing accelerated development of new and novel treatments.

At the same time, existing biochemical techniques are advancing to enhance the process of biotechnological research. X-ray crystallography and combinatorial chemistry are two examples of increased modernization. As discovery technologies more quickly determine greater numbers of targets, greater numbers of compounds will be reaching the clinical trial phase of development sooner.

The clinical trial is that segment of research in the drug development process that tests a product or device to determine such factors as safety, efficacy, and adverse reactions in a human population. This report will focus on the following:

Research and development of drugs and biologics and new applications for old drugs and devices

Major product pipelines in development for the top biotechnology and pharmaceutical companies

The impact of new technologies on the costs and processes of clinical trials. 

This report also addresses current and future trends in clinical trial research, how new focuses are driven by epidemiological trends, treatment of rare diseases, and the threat of bioterrorism.

INTENDED AUDIENCEThis report provides a thorough background of the clinical trial process. It is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and anyone interested in the clinical trials business and its future.

METHODOLOGYBoth primary and secondary research methodologies were used in preparing this study. Information contained in this report includes data obtained from government agencies, corporate publications, industry trade publications, and various news sources. Interviews were conducted with leaders from trade associations, universities, the Food and Drug Administration (FDA), and professional agencies. Further information was obtained through an extensive literature search. Forecasts were based on 10K filings, specific factors that could impact clinical trials, and conversations with industry insiders.

ANALYST CREDENTIALSJon Evans has been involved in business development and research for the medical industry since 1984. Mr. Evans' career includes 4 years as a diagnostic systems sales representative and over 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a BS in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

SCOPE OF REPORTThe report provides an overview of clinical development phases, the regulatory issues involved, and the factors influencing clinical trial costs. An overview is provided of new technologies that will be affecting the clinical trial process in the near future. Major product pipelines are provided by physiological system and company.

INFORMATION SOURCESInformation contained in this report includes data obtained from government agencies, corporate publications, industry trade publications, and various news sources. Interviews were conducted with leaders from trade associations, universities, the Food and Drug Administration (FDA), and professional agencies. Further information was obtained through an extensive literature search and conference attendance. Forecasts were based on 10K filings, specific factors that could impact clinical trials, and conversations with industry insiders.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

METHODOLOGY 2

ANALYST CREDENTIALS 2

SCOPE OF REPORT 2

INFORMATION SOURCES 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY 5

SUMMARY TABLE
U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, THROUGH 2014 6

SUMMARY FIGURE
U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, 2009-2014 ($ BILLIONS) 7

Chapter-3: OVERVIEW

TYPES OF CLINICAL TRIALS 8

CLINICAL TRIAL PHASES 8

WHO SPONSORS CLINICAL TRIALS? 8

TABLE 1 U.S. FORECAST OF SPONSORED CLINICAL TRIALS, THROUGH 2014 9

FIGURE 1 U.S. SPONSORED CLINICAL TRIALS MARKET, 2009-2014 ($ BILLIONS) 9

FIGURE 2 DRUG DEVELOPMENT TIME LINE 10

TABLE 2 PHASES OF THE CLINICAL TRIAL 10

PHASE I 11

PHASE II 11

PHASE III 12

PHASE IV/POST-MARKETING TRIALS 12

FACTORS AFFECTING STUDY SIZE 12

PHYSICIAN AND PATIENT RECRUITMENT 13

U.S. GOVERNMENT REGULATIONS 14

PHARMACEUTICALS AND BIOLOGICS 14

TABLE 3 U.S. LAWS AFFECTING DRUG APPROVAL TIMES 14

Additional U.S. Laws Affecting Clinical Trials 14

Health Insurance Portability and Accountability Act of 1996 (HIPAA) 14

Best Pharmaceuticals for Children Act (BPCA), 2002 15

TABLE 4 TOTAL APPROVED ACTIVE MOIETIES WITH NO MARKETING PROTECTION FOR WHICH FDA HAS ISSUED A WRITTEN REQUEST 16

FOOD AND DRUG ADMINISTRATION (FDA) 16

Background 16

Center for Biologics Evaluation and Research (CBER) 17

CBER and Bioterrorism 18

Center for Drug Evaluation and Research (CDER) 18

CDER and Bioterrorism 18

Critical Path Initiative (CPI) 19

MEDICAL DEVICES 19

Center for Devices and Radiologic Health (CDRH) 19

Articles Subject to Medical Device Amendments 19

Classification of Devices (General Section 513) 20

• Class I—General Controls 20

• Class II—Special Controls 20

• Class III 21

Expedited Review 21

FIGURE 3 NEW DRUG DEVELOPMENT 21

TABLE 5 CDER APPROVAL TIMES FOR PRIORITY AND STANDARD NDAS AND BLAS, CALENDAR YEARS, 1993 2008 22

Expedited Development and Review 22

TABLE 6 FIRST CYCLE APPROVAL RATE FOR OVERALL STUDY COHORT BY YEAR, 2002-2007 23

Subpart E 23

Accelerated Approval (Subpart H) 24

Priority Review 24

Fast Track 24

TABLE 7 NUMBER AND TOTAL APPROVAL TIME (IN MONTHS) OF APPROVED NDAS AND BLAS, BY FISCAL YEAR OF SUBMISSION AND BY REVIEW PROCEDURE 25

Pediatrics 25

U.S. LITIGATION AND CLINICAL TRIALS 25

TABLE 8 INSURANCE COMPANIES OFFERING CLINICAL TRIAL LIABILITY INSURANCE 26

INVESTIGATIONAL REVIEW BOARD (IRB) 26

EUROPEAN REGULATIONS 27

JAPANESE REGULATIONS 28

GLOBAL REGULATORY STANDARDS 28

INTERNATIONAL CONFERENCE OF HARMONIZATION (ICH) 28

International Conference of Harmonization … (Continued) 29

Chapter-4: CLINICAL TRIAL COST AND FUNDING

MANAGING CLINICAL TRIALS 30

CONTRACT RESEARCH ORGANIZATIONS (CROS) 31

CLINICAL TRIAL RESEARCH THERAPEUTIC AREAS 31

FIGURE 4 PHRMA MEMBER R&D FUNDING BY THERAPEUTIC CATEGORY, 2010 (% SHARE) 32

TABLE 9 BEST-SELLING PHARMACEUTICAL DRUGS WORLDWIDE, 2009 ($ BILLIONS) 33

TRENDS IN CLINICAL TRIALS 33

ELECTRONIC DATA CAPTURE (EDC) 33

CLINICAL TRIAL COSTS 34

FACTORS INFLUENCING CLINICAL TRIAL COSTS 34

Factors Increasing Clinical Trial Costs 34

Factors Increasing Clinical … (Continued) 35

Factors Decreasing Clinical Trial Costs 36

RECENT AND FUTURE TRENDS IN CLINICAL TRIAL PROCESSES 36

RESEARCH AND DEVELOPMENT BUDGETS 36

TABLE
INVESTMENT IN R&D AS A PERCENT OF SALES, PHARMACEUTICAL INDUSTRY, THROUGH 2014 (%) 37

TABLE 11 INVESTMENT IN R&D AS A PERCENT OF SALES, PHARMACEUTICAL INDUSTRY, THROUGH 2014, PHRMA MEMBERS, (%) 37

FUNDING CLINICAL TRIALS 38

TABLE 12
TOTAL R&D SPENDING BY SOURCE, THROUGH 2014 ($ BILLIONS) 39

TABLE 13
ESTIMATES OF NIH RESEARCH FUNDING FOR TOP 50 CONDITIONS AND DISEASE CATEGORIES, RESEARCH/DISEASE AREAS, THROUGH 2010 ($ MILLIONS/ROUNDED) 40

BIOTECH/PHARMACEUTICAL COMPANIES 41

TABLE 14 U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY INDUSTRY BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS) 42

NATIONAL INSTITUTES OF HEALTH AND OTHER FEDERAL AGENCIES OF THE FEDERAL GOVERNMENT 42

TABLE 15
U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY FEDERAL GOVERNMENT BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS) 43

PRIVATE ORGANIZATIONS, UNIVERSITIES, AND SPECIALTY GROUPS 43

TABLE 16 U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY UNIVERSITIES OR OTHER ORGANIZATIONS BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS) 44

TABLE 17 TOP 25 FOUNDATIONS AWARDING U.S.-FOCUSED GRANTS FOR GLOBAL HEALTH, RANKED BY NUMBER OF GRANTS AND DOLLAR AMOUNT, 2008 44

Private Organizations, Universities… (Continued) 45

Chapter-5: CLINICAL TRIAL PIPELINES AND TECHNOLOGY TRENDS

DRUGS BY SYSTEM 46

CARDIOVASCULAR 46

PhRMA Facts 46

PhRMA Facts (Continued) 47

TABLE 18 SELECTED CARDIOVASCULAR THERAPEUTICS IN DEVELOPMENT, 2010 48

CANCER 49

PhRMA Facts 49

PhRMA Facts (Continued) 50

TABLE 19 SELECTED ANTICANCER CRUGS IN DEVELOPMENT, 2010 51

CENTRAL NERVOUS SYSTEM 51

PhRMA Facts 52

TABLE 20 SELECTED CENTRAL NERVOUS SYSTEM THERAPEUTICS IN DEVELOPMENT, 2010 53

INFECTION 54

INFLAMMATION 54

RESPIRATORY 55

TABLE 21 CDER PRIORITY DRUG AND BIOLOGIC APPROVALS: CALENDAR YEAR 2009 55

TABLE 21 (CONTINUED) 56

DEVICES 56

BIOMEMS 56

STENTS 56

IMPLANTS 57

TABLE 22 MEDICAL DEVICES CLEARED OR APPROVED BY FDA IN 2010 57

TABLE 22 (CONTINUED) 58

TABLE 23 TOP MEDICAL DEVICE COMPANIES, IN TERMS OF 2009 REVENUES ($ MILLIONS) 58

BIOTECHNOLOGY VERSUS PHARMACEUTICAL 59

BIOLOGICS 60

TABLE 24 SELECTED BIOLOGICS IN DEVELOPMENT, 2010 60

TABLE 25 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY MODALITY, 2008 61

TABLE 26 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY INDICATION, 2008 62

TECHNOLOGIES 62

TABLE 27 NUMBER OF CLINICAL TRIALS USING NEW TECHNOLOGIES, THROUGH 2014 63

TABLE 28 NEW TECHNOLOGIES AND PROJECTED EFFECT ON CLINICAL TRIALS 64

ANTISENSE 64

APOPTOSIS 65

BIOCHIPS/MICROARRAYS 65

BIOINFORMATICS 65

BIOPROCESSORS 65

CELLS AND CELL SIGNALING 66

CELL THERAPY (I.E., STEM CELLS, TISSUE REPAIR) 66

CHEMICAL GENOMICS 67

CYTOMICS 67

ELECTRONIC DATA CAPTURE AND E-SUBMISSION 67

GENE THERAPY 67

GENOMICS 67

NOVEL DRUG DELIVERY SYSTEMS 68

PROTEOMICS 68

Four-part Definition of Proteomics 68

THERANOSTICS 69

TRANSGENICS 69

NANOTECHNOLOGY 69

NATURAL SOURCES 69

BIOMARKERS CONSORTIUM 69

NIH Public-Private Partnerships Policy Statement 69

FACTORS INFLUENCING DRUG DEVELOPMENT 70

FIGURE 5 FACTORS INFLUENCING DRUG DEVELOPMENT 71

EPIDEMIOLOGICAL TRENDS 71

LEGISLATION 71

NEW TECHNOLOGIES 72

BIOTERRORISM 72

Chapter-6: CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION

CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION 73

CONTRACT RESEARCH ORGANIZATIONS … (CONTINUED) 74

ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS FACTS 75

ASSOCIATION OF CLINICAL RESEARCH … (CONTINUED) 76

TABLE 29 TOP TEN CROS BY REVENUES, 2009 77

GLOBALIZATION 77

TABLE 30 CLINICAL TRIALS WITH OPEN ENROLLMENT BY REGION, JULY 2010 78

OUTSOURCING CLINICAL TRIALS TO FOREIGN COUNTRIES 78

TABLE 31 CLINICAL TRIALS RECRUITING SUBJECTS IN TARGETED COUNTRIES, JULY 2010 78

TABLE 31 (CONTINUED) 79

TABLE 32 AVERAGE COST PER PATIENT FOR TRIALS IN THE U.S., CANADA, AND WESTERN EUROPE FOR ALL THERAPEUTIC AREAS, THROUGH 2014 ($) 80

Advantages 80

Costs 80

TABLE 33 AVERAGE COST PER PATIENT FOR TRIALS IN REDUCED COST COUNTRIES, THROUGH 2014 ($) 81

Efficiency 81

Disadvantages 81

Sociopolitical Issues 82

BRAZIL 82

Patent Protection 82

Pharmaceutical and Clinical Trial Registration 82

Clinical Trials 82

TABLE 34 BRAZILIAN DOMESTIC PHARMACEUTICAL COMPANIES 83

CHINA 83

Patent Protection 83

Pharmaceutical and Clinical Trial Registration 83

Clinical Trials 83

Leading Chinese Pharmaceutical Companies 84

Beijing Double-Crane Pharmaceutical (DCPC) 84

Northeast General Pharmaceutical 84

Sanjiu Medical and Pharmaceutical Co., Ltd. 84

C & O Pharmaceutical Technology Holdings Ltd. 84

Shijiazhuang Pharma Group 84

Wuxi Pharmatech 84

Harbin Pharmaceutical Group Co. 85

INDIA 85

Advantages 85

Disadvantages 85

Key Points for Doing Clinical Studies in India 86

TABLE 35 INDIAN DOMESTIC PHARMACEUTICAL PRODUCERS 86

TABLE 36 INDIA'S DOMESTIC PHARMACEUTICAL MARKET (12 MONTHS ENDED JANUARY 2009) 87

TABLE 37 TOP FIVE BIOTECHNOLOGY COMPANIES IN INDIA 87

ROMANIA 87

Patent Protection 88

RUSSIA 88

Patent Protection 88

TABLE 38 LEADING RUSSIAN PHARMACEUTICAL COMPANIES 88

Chapter-7: BIOTECHNOLOGY COMPANIES

ACTELION PHARMACEUTICALS, LTD 89

TABLE 39 CLINICAL PIPELINE AS OF 12/31/2009 89

ALEXION PHARMACEUTICALS, INC. 90

TABLE 40 CLINICAL PIPELINE AS OF 12/31/2009 90

ALLERGAN, INC. 91

TABLE 41 CLINICAL PIPELINE AS OF 12/31/2009 91

TABLE 41 (CONTINUED) 92

ALSERES PHARMACEUTICALS, INC. 92

TABLE 42 CLINICAL PIPELINE AS OF 12/31/2009 92

AMGEN 93

TABLE 43 CLINICAL PIPELINE AS OF 12/31/2009 93

TABLE 43 (CONTINUED) 94

ARQULE 95

TABLE 44 CLINICAL PIPELINE AS OF 12/31/2009 95

ARRAY BIOPHARMA 96

TABLE 45 CLINICAL PIPELINE AS OF 12/31/2009 96

AVANIR PHARMACEUTICALS 97

TABLE 46 CLINICAL PIPELINE AS OF 12/31/2009 97

BAXTER BIOSCIENCE 98

TABLE 47 SAMPLE OF BAXTER'S CLINICAL TRIALS IN PROGRESS, AUGUST 2010 98

TABLE 47 (CONTINUED) 99

TABLE 47 (CONTINUED) 100

BIOCON 100

TABLE 48 CLINICAL PIPELINE AS OF 12/31/2009 101

BIOGEN IDEC 101

TABLE 49 CLINICAL PIPELINE AS OF 12/31/2009 101

TABLE 49 (CONTINUED) 102

CELGENE CORP 102

TABLE 50 CLINICAL PIPELINE AS OF 12/31/2009 103

CELL THRAPEUTICS 103

TABLE 51 CLINICAL PIPELINE AS OF 12/31/2009 104

CELLDEX THERAPEUTICS 104

TABLE 52 CLINICAL PIPELINE AS OF 12/31/2009 105

CEPHALON, INC. 105

TABLE 53 CLINICAL PIPELINE AS OF 12/31/2009 106

CSL BEHRING (CSL, LTD) 106

TABLE 54 CLINICAL PIPELINE AS OF 12/31/2009 107

CYTOKINETICS 107

TABLE 55 CLINICAL PIPELINE AS OF 12/31/2009 108

DENDREON 108

TABLE 56 CLINICAL PIPELINE AS OF 12/31/2009 109

DYNAVAX TECHNOLOGIES 110

TABLE 57 CLINICAL PIPELINE AS OF 12/31/2009 110

ELAN 110

TABLE 58 CLINICAL PIPELINE AS OF 12/31/2009 111

ENZON PHARMACEUTICALS 111

TABLE 59 CLINICAL PIPELINE AS OF 12/31/2009 112

EPICEPT CORPORATION 112

TABLE 60 CLINICAL PIPELINE AS OF 12/31/2009 113

GENENTECH 113

TABLE 61 CLINICAL PIPELINE AS OF 12/31/2009 114

TABLE 61 (CONTINUED) 115

GENZYME 116

TABLE 62 CLINICAL PIPELINE AS OF 12/31/2009 117

GILEAD 117

TABLE 63 CLINICAL PIPELINE AS OF 12/31/2009 118

GTC BIOTHERAPEUTICS, INC. 119

TABLE 64 CLINICAL PIPELINE AS OF 12/31/2009 119

GTX 120

TABLE 65 CLINICAL PIPELINE AS OF 12/31/2009 120

HUMAN GENOME SCIENCES 120

TABLE 66 CLINICAL PIPELINE AS OF 12/31/2009 121

IDERA PHARMACEUTICALS, INC. 121

TABLE 67 CLINICAL PIPELINE AS OF 12/31/2009 122

IMMUNOGEN, INC. 122

TABLE 68 CLINICAL PIPELINE AS OF 12/31/2009 123

IMMUNOMEDICS, INC. 123

TABLE 69 CLINICAL PIPELINE AS OF 12/31/2009 124

LORUS THERAPEUTICS INC. 124

TABLE 70 CLINICAL PIPELINE AS OF 12/31/2009 124

MAXYGEN 125

TABLE 71 CLINICAL PIPELINE AS OF 12/31/2009 125

MYRIAD PHARMACEUTICALS, INC. 125

TABLE 72 CLINICAL PIPELINE AS OF 12/31/2009 126

NOVO NORDISK A/S 126

TABLE 73 CLINICAL PIPELINE AS OF 12/31/2009 127

NPS PHARMACEUTICALS, INC. 127

TABLE 74 CLINICAL PIPELINE AS OF 12/31/2009 128

REPLIGEN CORPORATION 128

TABLE 75 CLINICAL PIPELINE AS OF 12/31/2009 129

SANGAMO BIOSCIENCES, INC. 129

TABLE 76 CLINICAL PIPELINE AS OF 12/31/2009 129

SEATTLE GENETICS, INC. 130

TABLE 77 CLINICAL PIPELINE AS OF 12/31/2009 130

TALECRIS BIOTHERAPEUTICS, INC. 131

TABLE 78 CLINICAL PIPELINE AS OF 12/31/2009 131

UCB SA 132

TABLE 79 CLINICAL PIPELINE AS OF 12/31/2009 132

URIGEN PHARMACEUTICALS, INC. 133

TABLE 80 CLINICAL PIPELINE AS OF 12/31/2009 133

VERTEX PHARMACEUTICALS INCORPORATED 133

TABLE 81 CLINICAL PIPELINE AS OF 12/31/2009 134

VICAL, INCORPORATED 134

TABLE 82 CLINICAL PIPELINE AS OF 12/31/2009 135

XOMA, LTD. 135

TABLE 83 CLINICAL PIPELINE AS OF 12/31/2009 136

Chapter-8: PHARMACEUTICAL COMPANIES

ABBOTT LABORATORIES 137

TABLE 84 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 137

ASTRAZENECA PLC 138

TABLE 85 CLINICAL PIPELINE AS OF 12/31/2009 138

TABLE 85 (CONTINUED) 139

TABLE 85 (CONTINUED) 140

TABLE 85 (CONTINUED) 141

BAYER SCHERING PHARMA AG 141

TABLE 86 PHASE II/III CLINICAL PIPELINE AS OF 12/31/2009 142

TABLE 86 (CONTINUED) 143

BOEHRINGER INGELHEIM GMBH 143

TABLE 87 CLINICAL PIPELINE AS OF 12/31/2009 144

BRISTOL-MYERS SQUIBB COMPANY 144

TABLE 88 CLINICAL PIPELINE, SELECTED PHASE I/II CANDIDATES AS OF 12/31/2009 145

TABLE 88 (CONTINUED) 146

TABLE 89 INVESTIGATIONAL CANDIDATES IN PHASE III CLINICAL TRIALS 146

ELI LILLY AND COMPANY 147

TABLE 90 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 147

GLAXOSMITHKLINE PLC 148

TABLE 91 CLINICAL PIPELINE AS OF 12/31/2009 148

TABLE 91 (CONTINUED) 149

TABLE 91 (CONTINUED) 150

TABLE 91 (CONTINUED) 151

TABLE 91 (CONTINUED) 152

JOHNSON & JOHNSON 152

TABLE 92 SELECTED PHASE III CLINICAL PIPELINE AS OF 12/31/2009 153

MERCK & CO., INC. 154

TABLE 93 CLINICAL PIPELINE AS OF 12/31/2009 154

TABLE 93 (CONTINUED) 155

MERCK SERONO 155

TABLE 94 CLINICAL PIPELINE AS OF 12/31/2009 156

NOVARTIS AG 156

TABLE 95 CLINICAL PIPELINE AS OF 12/31/2009 157

TABLE 95 (CONTINUED) 158

TABLE 95 (CONTINUED) 159

TABLE 95 (CONTINUED) 160

TABLE 95 (CONTINUED) 161

PFIZER, INC. 161

TABLE 96 CLINICAL PIPELINE AS OF 12/31/2009 162

TABLE 96 (CONTINUED) 163

TABLE 96 (CONTINUED) 164

TABLE 96 (CONTINUED) 165

ROCHE 165

TABLE 97 CLINICAL PIPELINE AS OF 12/31/2009 166

TABLE 97 (CONTINUED) 167

TABLE 97 (CONTINUED) 168

SANOFI-AVENTIS 168

TABLE 98 CLINICAL PIPELINE AS OF 12/31/2009 169

TABLE 98 (CONTINUED) 170

TAKEDA PHARMACEUTICAL COMPANY LIMITED 171

TABLE 99 CLINICAL PIPELINE AS OF 12/31/2009 172

TABLE 99 (CONTINUED) 173

TABLE 99 (CONTINUED) 174

TABLE 99 (CONTINUED) 175

Chapter-9: MEDICAL EQUIPMENT AND DEVICES

TABLE 100 MEDICAL EQUIPMENT AND DEVICE COMPANIES IN THE U.S. WITH ANNUAL REVENUES EXCEEDING $1 BILLION 176

TABLE 100 (CONTINUED) 177

TABLE 100 (CONTINUED) 178

TABLE 100 (CONTINUED) 179

Chapter-10: CLINICAL RESEARCH ORGANIZATIONS

TOP 10 CROS 180

TABLE 101 TOP 10 CROS BY REVENUE (ACCOUNTED FOR MORE THAN 50% OF TOTAL INDUSTRY REVENUE IN 2008/2009) 180

SECONDARY CROS (ALPHABETICAL ORDER) 180

TABLE 102
SECONDARY CROS (ALPHABETICAL ORDER) 180

TABLE 102 (CONTINUED) 181

NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER) 181

TABLE 103
NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER) 181

TABLE 103 (CONTINUED) 182

To order this report:Drug Discovery and Development Industry: The Clinical Trials Business

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.com US: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Pharmaceutical Key Trends 2010
2. Reportlinker Adds Antiemetics: Technologies and Global Markets
3. Reportlinker Adds Anti-Counterfeiting Packaging Technologies in the Global Pharmaceutical and Food Industries
4. Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011
5. Reportlinker Adds U.S. Market for Patient Monitoring Devices 2011
6. Reportlinker Adds European Markets for Video, High-Tech and Integrated OT Equipment 2011
7. Reportlinker Adds Corporate Strategies in Consumer Health 2010
8. Reportlinker Adds Allergic Conjunctivitis - Pipeline Assessment and Market Forecasts to 2017
9. Reportlinker Adds Chinese Markets for Drug Delivery System
10. Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
11. Reportlinker Adds Asia-Pacific Endoscopy Devices Market Outlook to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Compliancy Group LLC is pleased to offer ... the country. The Guard was specifically designed to handle each element required for ... updates, and compliance coaching. , In addition to meeting the compliance needs of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize ... can leave patients with dental emergencies at risk of losing a tooth or their ... care. , Common dental emergencies include:, , Avulsed or ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... Indianapolis, IN (PRWEB) , ... February 10, 2016 ... ... employee benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its ... and has seven other locations throughout the Southeast, from Orlando to Huntsville and ...
Breaking Medicine News(10 mins):